HR Execs on the Move


 
Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the-counter (OTC) remedies. We market our products in more than 165 countries and territories, and every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world. Mylans mission is grounded in our belief that every person matters and should have the opportunity to live the healthiest life possible. We have ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.mylan.com
  • 1000 Mylan Boulevard
    Canonsburg, PA USA 15317
  • Phone: 724.514.1800

Executives

Name Title Contact Details
Sachin Kulkarni
Senior Director, R&D and Manufacturing Technical Services Profile
Kristina Mesic
VP Global Supply Chain, Complex Products Profile
Peter McCormick
Senior Vice President - Manufacturing Supply - Global Pharmaceutical Operations - Retiring March 2013 Profile
John Metcalf
Human Resources Director Developed Markets Profile
Angela Grimm
Director of North America Human Resources Business Services Profile

Similar Companies

QCL Quality Compliance Laboratories Inc

QCL Quality Compliance Laboratories Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Novum

Novum is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers R1`s proven and scalable operating models seamlessly complement a healthcare organization`s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience.

Kiel Laboratories

Kiel Laboratories, Inc. is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.